Sequel Blu GmbH
Matthias Steger PhD, MBA is an experienced leader in the pharmaceutical and biotechnology sectors, currently serving as General Partner at Sequel Blu GmbH since November 2014, where expertise includes drug discovery strategies and fostering collaborations for transformational innovation. Previous roles include CEO at ENDOGENA THERAPEUTICS from August 2016 to October 2024 and at Rejuveron Life Sciences AG from July 2019 to June 2022, focusing on the development of technologies to extend human lifespan and combat age-related diseases. Matthias Steger also held positions as Global Head of Research & Technology Partnering at Hoffmann-La Roche and as a financial analyst at Kepler Equities. Academic qualifications include a PhD in Medicinal Chemistry from the University of Sussex, an MBA from the University of St.Gallen, and a Master's degree in Organic Chemistry from the University of Zurich.
This person is not in the org chart
This person is not in any teams
Sequel Blu GmbH
Together with our clients and partners we develop sustainable strategies. With dedication, creativity and stamina, we will accompany you every step of the way on the path to full implementation. With measurable and relevant results towards a viable future society.